BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN BEGIN:VEVENT UID:672@biocityturku.fi DTSTART;TZID=Europe/Helsinki:20241002T150000 DTEND;TZID=Europe/Helsinki:20241002T160000 DTSTAMP:20240923T053735Z URL:https://biocityturku.fi/events/fican-west-guest-lecture-tilley/ SUMMARY:FICAN West Guest Lecture\, Tilley DESCRIPTION:2nd October at 15:00\nOn-site event\nin Medisiina D 8th  floor \, Reseptori\n\nProfessor Wayne D Tilley\, Director\, Dame Roma Mitchell C ancer Research Laboratories (DRMCRL)\, Adelaide Medical School\, the Unive rsity of Adelaide\, Australia\nExploiting sex hormone cross-talk as an alt ernative endocrine therapy for ER+ breast cancers\n\nIn case you wanted to have a 1:1 researcher discussion with Wayne Tilley on Tuesday October 1st \, please reply by Wed Sept 25 to mertor@utu.fi.\n\n \n\nProfessor Wayne Tilley is the Inaugural Director of the Dame Roma Mitchell Cancer Research Laboratories (DRMCRL)\, Adelaide Medical School\, the University of Adela ide (2002-current). He was one of the first to clone the human androgen re ceptor and is internationally recognized for his subsequent research on th e role of sex hormones (estrogens\, progestogens and androgens) in hormone -dependent cancers\, in particular breast and prostate cancer.\n\nProf Til ley received the 2016 Endocrine Society of Australia Senior Plenary Award for outstanding research in the field of endocrinology and presented the o pening plenary lecture at the International Congress of Endocrinology in B eijing. In 2023 he was awarded the Rob Sutherland Translational Award by B reast Cancer Trials Australia in recognition of excellence in scientific a nd translational research and achievements and contributions to improved p atient outcomes.\n\nHe has convened multiple conferences on sex-hormone ac tion and hormone-dependent cancers\, including the Fusion Nuclear Receptor and International Breast Cancer Society meetings\, Gordon Research Confer ence on Hormone-Dependent Cancers\, and the International PacRim Breast an d Prostate Cancer meeting series.\n\n \;\n\nSeminar Abstract by profes sor Tilley\n\nEndocrine therapies that target the estrogen receptor (ER) a re the cornerstone of treatment for ER+ breast cancer\, but treatment-resi stant\, metastatic disease develops in ~30% of cases and causes >\;60% o f breast cancer related deaths. These endocrine therapy-resistant breast c ancers almost invariably remain dependent on ER\, so research and drug dev elopment has largely remained focused on achieving more effective eliminat ion of ER signalling\, most recently via drugs that degrade ER (selective ER degraders\, SERDs). Our laboratory has been investigating the stimulati on of other sex hormone receptors as an alternative endocrine therapeutic strategy to treat ER+ breast cancers. Historically\, treatment with androg enic (testosterone propionate\, fluoxymesterone) or progestogenic (medroxy -progesterone acetate\, megestrol) drugs was associated with disease regre ssion in up to 30% of patients with advanced breast cancer in the absence of knowing the sex hormone receptor status of the tumour or a biomarker of response. Despite the clinical benefit of these alternative endocrine app roaches\, such therapies were discontinued with the advent of anti-estroge nic drugs in the 1980’s\, in particular tamoxifen and later\, aromatase inhibitors (AIs).\n\nUsing contemporary pre-clinical models\, we have esta blished that both the androgen receptor (AR) and progesterone receptor (PR ) can function as tumour suppressors in ER+ breast cancer (Hickey et al\, Nature Medicine 2021\; Mohammed et al\, Nature 2015). These preclinical st udies have been validated by recent clinical studies demonstrating that ag onist activation of either the AR or PR has efficacy in women with ER+ bre ast cancer. Selective AR modulators (SARMs) have a high specificity for bi nding to AR\, act in a tissue-selective manner\, and do not cause virilisi ng effects in women. Enobosarm (GTx-024) is a non-steroidal SARM that dura bly inhibits in-vivo growth of ER+ breast cancer (Hickey et al\, Nature Me dicine 2021). We recently reported (Palmieri et al\, Lancet Oncology 2024) that enobosarm has anti-tumour activity in patients with ER+\, HER- negat ive advanced breast cancer\, indicating that AR activation can result in c linical benefit\, and supporting further clinical investigation of selecti ve AR activation strategies. Additionally\, Burrell et al (SABCS\, 2023) r eported the clinical activity of megestrol\, a PR agonist\, in early-stage ER+ breast cancer. In the latter study\, megestrol enhanced the antitumor effect of an AI\, and alleviated hot flashes associated with AI treatment .\n\nOur most recent preclinical studies indicate that AR agonism is effec tive in the context of disease sensitive to or resistant to standard-of-ca re endocrine therapies\, with or without inhibition of cyclin-dependent ki nase (CDK) 4/6. We have also found that a viable surrogate biomarker of ho rmonal therapy in the breast\, namely background parenchymal enhancement ( BPE)\, can be significantly reduced by AR agonism with a female-tailored d ose of testosterone\, whilst having very good tolerability. This finding p aves the way for a trial to test AR agonism as a primary preventative stra tegy for breast cancer.\n\nIn this seminar\, I will discuss the above-ment ioned findings and our recent work to further elucidate the mechanisms of AR and PR mediated tumour suppression in ER+ breast cancer.\n\n \;\n\n Note also the FoS seminar on same day at 12:00 on a closely related topic\ , by Prof. Carlos L. Arteaga. https://biocityturku.fi/events-archive/front iers-of-science-prof/ ATTACH;FMTTYPE=image/jpeg:https://biocityturku.fi/wp-content/uploads/Fican -West-thumbnail.jpg CATEGORIES:Other events END:VEVENT BEGIN:VTIMEZONE TZID:Europe/Helsinki X-LIC-LOCATION:Europe/Helsinki BEGIN:DAYLIGHT DTSTART:20240331T040000 TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST END:DAYLIGHT END:VTIMEZONE END:VCALENDAR